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21% in the second, 53% in the third, and 94% in the fourth line. The most common 
treatment algorithm (18%) was FOLFOX, FOLFIRI and supportive care in the ﬁ rst-, 
second-, and third-lines, respectively. Mean regimen costs per patient were estimated 
from a public payer perspective. The most expensive ﬁ rst, second, third and fourth-line 
regimens were FOLFOX 4 (c14,200), FOLFIRI + bevacizumab (c7912c), cetuximab 
+ irinotecan (c7237) and capecitabine (c2609), respectively. CONCLUSIONS: The 
most common regimen in the ﬁ rst line was also the most expensive one. New chemo-
therapeutic agents are associated with improvements in survival time but also with 
substantial costs. Factors inﬂ uencing the selection of chemotherapy included: previous 
therapies, course of the disease, the patient’s performance status, adverse events after 
previous chemotherapies, and concomitant diseases. However, open-ended coverage 
policies for new chemotherapeutic agents may prove difﬁ cult to sustain as costs 
continue to rise.
PCN59
COST OF MANAGEMENT OF BREAST CANCER WITH BRAIN 
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OBJECTIVES: Breast cancer (BC) is the second neoplasm which disseminates brain 
metastases (BM). We estimated the incidence of patients with BCBM, those overex-
pressing HER2 (HER2+), and the costs related to their management using the new 
chaining system of the French hospital information program (PMSI). This was to 
identify predictors of costs. METHODS: A retrospective analysis using the PMSI 
database (2006–2008) was conducted to estimate the number of public and private 
stays related to the diagnosis of BCBM. Stays were extracted and chained to patients’ 
identiﬁ cation number to calculate the number of patients concerned by BCBM. The 
administration of trastuzumab was used as a surrogate for the HER2 status. Costs 
were estimated from the health insurance perspective including health-related group 
tariff, supplements for intensive care, number and length of stays, and expensive-drugs 
status. Spearman’s rank correlation coefﬁ cient and nonparametric test (Kruskal–
Wallis) were used for univariate analyses. RESULTS: In 2008, 3610 women were 
hospitalized for BCBM (vs. 3273 and 3523 in 2006 and 2007, respectively) of whom 
average age was 56.1 years (SD: 13.3). Patients had an average of 4.8 hospitalizations 
(SD: 6.4) mostly for palliative care (42%), chemotherapy (39%), and radiotherapy 
(14%). Twenty-one percent of patients suffered from BM only and 79% had multiple 
metastases; 16% were identiﬁ ed as HER2+. Annual mean cost of care was c8049 per 
patient with BCBM compared with c19,412 speciﬁ cally for HER2+ patients (respec-
tively, 11% and 59% were dedicated to expensive drugs). Age (P < 0.001), patients 
with newly diagnosed BCBM (P < 0.001), and the number of metastases (P < 0.001) 
were associated with the cost of BCBM. CONCLUSIONS: Incidence of BCBM seemed 
to increase during 2006–2008. BCBM management appeared resource-consuming 
especially for HER2+ patients. The development of chaining system in PMSI database 
is an opportunity to estimate economic data accurately as well as to generate epide-
miological data from an exhaustive database.
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OBJECTIVES: Chemotherapy is a major factor contributing to the economic burden 
associated with breast cancer in the elderly. However, there are no clear recommenda-
tions for adjuvant chemotherapy use in elderly women aged 70 and above due to lack 
of efﬁ cacy data in that age group. The study objective was to examine the clinical and 
economic outcomes associated with adjuvant chemotherapy in elderly patients aged 
65 and above with early stage operable breast cancer. METHODS: We studied a 
cohort of 23,110 node positive and 31,572 node negative women aged 65 and over 
diagnosed with incident American Joint Committee on Cancer (AJCC) stage I, II, or 
IIIa breast cancer between January 1, 1991 and December 31, 2002 using SEER-
Medicare data. Total treatment and chemotherapy costs were estimated from the 
Medicare payments using the phase of care approach. Cox proportional hazard ratio 
of mortality was used to determine the effectiveness of adjuvant chemotherapy after 
adjusting for selected patient and tumor characteristics. a propensity score analysis 
was also employed to minimize the bias associated with the receipt of adjuvant che-
motherapy. RESULTS: The difference in the total unadjusted costs for patients who 
received chemotherapy in contrast with patients not receiving any chemotherapy was 
$16,795 in node positive patients and $11,882 in node negative patients. Regression 
adjusted cost estimates for all node positive patients receiving chemotherapy was 
approximately $6500 and was signiﬁ cantly higher (P < 0.05) than for patients not 
receiving chemotherapy. Mortality was signiﬁ cantly reduced in node positive women 
aged 65–69 who received adjuvant chemotherapy compared to those who did not 
receive chemotherapy (HR, 0.66; CI, 0.58–0.74) and in patients aged 70–74 (HR,0.66; 
CI, 0.59–0.74), after adjustment for factors that may affect survival. CONCLUSIONS: 
Decision makers can use cost and effectiveness estimates from this study to assess rela-
tive value of chemotherapy in different age groups.
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OBJECTIVES: To evaluate the cost of biweekly oxaliplatin plus oral capecitabine 
(OXXEL) versus oxaliplatin combined with leucovorin-modulated 5-ﬂ uorouracil 
(5-FU) given as i.v. bolus every 2 weeks (OXAFAFU) in patients with metastatic 
colorectal cancer (MCRC) in Italy. METHODS: We conducted a multicenter, retro-
spective longitudinal treatment-cost analysis. Direct medical costs attributable to 
MCRC were quantiﬁ ed using 2008 prices and tariffs. The analysis was applied to a 
time horizon of 6 months. The study was conducted from the perspective of the 
National Healthcare Service (NHS). RESULTS: A total of 322 patients (59.9% males; 
mean age 65.2 ± 9.4 years) were analyzed. Mean total cost per patient over follow-up 
period was estimated at c5242.18 ± 2542.06 and c6732.80 ± 3423.72 in the 
Capecitabine and 5-FU arms respectively (P < 0.0001). CONCLUSIONS: The study 
estimated that oral capecitabine administration would produce a saving of c1490.62 
to the NHS. The differences in cost between the two arms are determined by the 
administration route (i.v. vs. oral administration). Therefore, the important economic 
and practical advantage of capecitabine oral home-based therapy is the reduced 
number of hospital visit and the relative costs. Avoiding the hospital access fees 
reduces the impact of higher acquisition cost of capecitabine. Moreover, capecitabine 
in comparison to the 5-FU regimen was associated with lower complication. There-
fore, oral capecitabine may represent a valid alternative in the management of meta-
static colorectal cancer.
PCN62
SURVEY AND ANALYSIS OF THE COSTS OF METASTATIC 
COLORECTAL CANCER TREATMENT IN SLOVAKIA
Rutkowski J1, Haldas M1, Salek T2, Jedynasty K3
1HTA Consulting, Krakow, Poland; 2National Cancer Institute, Bratislava, Slovak Republic; 
3Amgen GmbH, Headquarters Ofﬁ ce for CEE, Vienna, Austria
OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst-, second-, and 
third-line treatment of patients with metastatic colorectal cancer and to estimate costs 
of regimens, supportive care, and medical procedures in Slovakia (part of a multina-
tional study in central Europe). METHODS: In this opinion-based study, data were 
collected by online questionnaire. All information concerning treatment of colorectal 
cancer was based on expert opinion at three oncology centers in Slovakia. Oncologists 
had access to medical records of approximately 1600 patients treated in year 2008. 
RESULTS: The most commonly used ﬁ rst-line regimen (27% of patients) was IFL 
(irinotecan, 5-FU, leucovorin) + bevacizumab. The most commonly prescribed second-
line regimen (27%) was cetuximab + irinotecan and capecitabine was the most 
common third-line regimen (15%). None of patients received supportive care in the 
ﬁ rst line. The percentages of patients receiving supportive care in the second and third 
lines were 27% and 45%, respectively. The most common treatment strategy (8%) 
was ﬁ rst-line capecitabine and supportive care in the second line. Mean regimen costs 
per patient were estimated from a public payer perspective. The most expensive ﬁ rst-
line regimen was IFL + bevacizumab (c36,369). In the second and third lines, modiﬁ ed 
FOLFOX 4 (oxaliplatin, 5-FU, leucovorin) was the most expensive regimen at c31,318 
and c31,572, respectively. CONCLUSIONS: More than 50% of patients received an 
active treatment until the second line. The most common regimen in the ﬁ rst line was 
also the most expensive one. New chemotherapeutic agents are associated with 
improvements in survival time but also with substantial costs. Factors inﬂ uencing the 
selection of chemotherapy included: previous therapies, course of the disease, the 
patient’s performance status, adverse events after previous chemotherapies and con-
comitant diseases. However, open-ended coverage policies for new chemotherapeutic 
agents may prove difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: To describe chemotherapy regimens used and to estimate costs of 
chemotherapy regimens, supportive care, and medical procedures in the ﬁ rst-, second-, 
third-, and fourth-line treatment of patients with metastatic colorectal cancer in Serbia 
(part of a multinational study in central Europe). METHODS: An online questionnaire 
was used to collect necessary information in this opinion-based study. All information 
concerning treatment of colorectal cancer was based on experts opinion from four 
oncology centers in Serbia. Oncologists had access to medical records of approxi-
mately 1760 patients treated in year 2008. RESULTS: The leading ﬁ rst-line regimen 
(38% of patients) was Mayo (Folinic acid, 5-FU). The most commonly prescribed 
second-line regimen (46%%) was FOLFOX 4. Modiﬁ ed FOLFIRI (irinotecan, folinic 
acid, 5-FU) was the most popular regimen in the third line (35%), while FOLFIRI/
cetuximab (35%) was the most commonly used fourth-line regimen. The percentage 
of patients receiving supportive care was 7%, 5%, 10%, and 56% in the ﬁ rst, second, 
third, and fourth lines, respectively. The most common treatment path (8%) was 
FOLFOX 4 B in the ﬁ rst line, FOLFIRI B in the second, and Mitomicin mono in the 
third. Mean regimen costs per patient were estimated from a public payer perspective. 
The most expensive regimen in the ﬁ rst line was bevacizumab + capecitabine + oxali-
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platin (c21,126), the same regimen was also the most expensive in the second line 
(c13,366), irinotecan/cetuximab in the third line (c25,633), and FOLFIRI/cetuximab 
in the fourth line (c6479). CONCLUSIONS: New chemotherapeutic agents are associ-
ated with improvements in survival time but also with substantial costs. Factors 
inﬂ uencing the selection of chemotherapy included: previous therapies, course of the 
disease, the patient’s performance status, adverse events after previous chemothera-
pies, and concomitant diseases. However, open-ended coverage policies for new che-
motherapeutic agents may prove difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst-, second-, third-, 
and fourth-line treatment of patients with metastatic colorectal cancer and to estimate 
costs of chemotherapy regimens, supportive care, and medical procedures in Slovenia 
(part of a multinational study in central Europe). METHODS: In this opinion-based 
study, necessary data were collected by online questionnaire. All information concern-
ing treatment of colorectal cancer was based on experts opinion from an oncology 
center in Slovenia. Oncologist had access to medical records of approximately 800 
patients treated in year 2008. RESULTS: The most commonly used regimen in the 
ﬁ rst line (30% of patients) was XELIRI (capecitabine, irinotecan) + bevacizumab. The 
most commonly prescribed regimen in the second (28%) and third lines (12%) was 
XELOX (capecitabine, oxaliplatin) + bevacizumab. XELIRI + bevacizumab was most 
commonly used in the fourth line (6%). Supportive care was not used in the ﬁ rst line 
with 9%, 55%, and 76% receiving it in the second, third, and fourth lines, respec-
tively. The most common treatment algorithm (21% of patients) was ﬁ rst-line XELIRI 
+ bevacizumab and second-line XELOX + bevacizumab. Mean regimen costs per 
patient were estimated from a public payer perspective. FOLFOX + cetuximab was 
the most expensive regimen in all lines. Costs of this regimen were c35,896 in the ﬁ rst 
line and c36,179 in the second, third, and fourth lines. CONCLUSIONS: More than 
50% of patients received an active treatment until the second line. Costs of treatment 
vary between lines. New chemotherapeutic agents are associated with improvements 
in survival time but also with substantial costs. Factors inﬂ uencing the selection of 
chemotherapy included: previous therapies, course of the disease, the patient’s perfor-
mance status, adverse events after previous chemotherapies, and concomitant diseases. 
However, open-ended coverage policies for new chemotherapeutic agents may prove 
difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common forms of cancer 
in western countries and represents the second leading cause of cancer mortality in 
Europe (AIRTUM 2009). Early detection and removal of cancerous lesions can reduce 
CRC and mortality and improve patients’ quality of life (Taupin et al. 2006). The 
main literature on this topic refers to the United States and few studies have been 
conducted in Italy to date (Zappa et al. 1997; Tappenden 2007). Aim of the paper is 
to shed some light on the effectiveness and costs of screening programs in the Italian 
health-care system, presenting the results of a cost-effectiveness analysis of a CRC 
screening program in Italy. METHODS: We use as case study a Regional CRC screen-
ing program to determine the full costs and the effectiveness of the adopted techniques, 
FOBT combined with colonoscopy.The costs involved in each phase of the program 
are evaluated using a microcosting analysis. Effectiveness is valued in terms of early 
detected lesions and years of life gained. Cost and effectiveness data are used to 
estimate the costs for year of life gained, using a MISCAN-COLON Model© to simu-
late and compare two alternative scenarios, with or without the screening program. 
RESULTS: The preliminary results show that the screening will prevent almost 2.0 
deaths (11.2%) per 1000 screened individuals, corresponding to 19.4 years of life 
gained in 30 years with an incremental cost-effectiveness ratio of c2.400 for life-year 
gained. CONCLUSIONS: The results outpace those of previous studies (Sonnenberg 
2000), signaling an increasing effectiveness of CRC screening program. Besides, the 
paper highlights the importance of implementing a screening not only for the effects 
that prevention can have in clinical terms, but also for the economic impact of such 
a policy in relation to the long-term sustainability of health-care systems.
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OBJECTIVES: The objective of the study was to examine the direct medical cost of 
XELOX (capecitabine plus oxaliplatin) compared to FOLFOX (ﬂ uorouracil/leucovo-
rin plus oxaliplatin) for the treatment of advanced colon-rectum cancer in China. 
METHODS: Since the equal efﬁ cacy was already demonstrated by the published lit-
erature and local clinical guideline, cost minimization analysis was performed to 
compare the direct medical costs of XELOX and FOLFOX for the treatment of 
advanced colon-rectum cancer. The direct medical costs were associated with the drug 
costs, drug administration costs, hospitalization costs, and adverse events management 
costs. The costs were calculated based on a questionnaire survey from an expert panel 
of 23 pharmacists and 10 gastrointestinal surgeons and medical oncologists. 
RESULTS: According to the recommendation of expert panel, the standard treatment 
duration of XELOX and FOLFOX was eight cycles and 12 cycles, respectively. The 
drug cost of XELOX regimen was CNY 47,306 (US$6926), higher than FOLFOX by 
CNY 22,118 (US$3238). However, the cost increment of XELOX regimen was offset 
by the higher drug administration cost (deviation CNY 6,820), hospitalization cost 
(deviation CNY 10,200), and adverse events management cost (deviation CNY 7,710) 
of FOLFOX regimen. As a result, XELOX showed a signiﬁ cant overall cost savings 
of CNY 2612 (US$382) compared with FOLFOX. CONCLUSIONS: According to 
the study, XELOX is cost saving in comparison with FOLFOX for the treatment of 
advanced colon-rectum cancer in China, especially in the chemotherapy administra-
tion and hospitalization utilization.
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OBJECTIVES: To describe treatment patterns, resource use, and associated costs for 
cancer patients with malignant ascites (MA) receiving paracentesis in Germany. 
METHODS: The study was conducted as an observational, multicenter, prevalence-
based cohort study. Inclusion criteria were: age ≥18 years, diagnosis of ovarian or 
gastrointestinal carcinoma (CA) with MA, paracentesis as treatment option for MA 
at the time of enrolment. Resource consumption data were collected by chart review 
and patient questionnaire covering the time period from the ﬁ rst paracentesis docu-
mented in the study until ascites diagnosis retrospectively and subsequent paracenteses 
prospectively. Direct medical costs were analyzed from third-party payers’ (TPP) and 
patients’ perspective. RESULTS: A total of 29 patients (38% male) with a mean age 
of 65 ± 9 years were enrolled at 11 centers (six hospitals, ﬁ ve ofﬁ ce-based practices) 
between July 2008 and August 2009. Seven patients had ovarian CA (24%), 5 gastric 
CA (17%), and 17 other gastrointestinal CAs (59%). a total of 101 paracenteses were 
documented for all patients. From ascites diagnosis to death patients received on 
average 4.6 paracenteses. Mean time between two paracenteses was 11.9 ± 12.3 days. 
Data from 42 paracenteses were eligible for resource and cost analysis. Diuretics were 
applied in 57% of paracentesis units and human albumin in 29%. Intraperitoneal 
chemotherapy was applied rarely (5%). From TPPs’ perspective, mean total costs per 
paracentesis unit amounted to c1064 ± 1453, from patients’ perspective c17 ± 46. 
Direct medical costs per paracentesis unit varied from c671 ± 1070 at ofﬁ ce-based 
practices to c2.742 ± 1.535 at hospitals (inpatient treatment). CONCLUSIONS: This 
is the ﬁ rst comprehensive study evaluating the burden of MA in cancer patients 
undergoing paracentesis in Germany. Our ﬁ ndings indicate that the costs for paracen-
tesis range around c670 to c2700 depending on health-care setting. Our results might 
serve as a basis for further research on the economic implication of malignant ascites.
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FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II 
BREAST CANCER PATIENTS IN GERMANY
Taylor DC1, Ozer-Deniz S1, Hill G1, Skornicki M1, Danel A2, Kunz E3
1i3 Innovus, Medford, MA, USA; 2Amgen (Europe) GmbH, Zug, Switzerland; 3Amgen 
(Europe) GmbH, München, Germany
OBJECTIVES: To assess the cost-effectiveness in Germany of primary prophylaxis 
(PP) with pegﬁ lgrastim versus 6- or 11-day ﬁ lgrastim (F6, F11) in the prevention of 
febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients receiving 
CHOP-14 chemotherapy and in breast cancer (BC) patients receiving TAC chemo-
therapy. METHODS: A payer perspective Markov model of febrile neutropenia pro-
phylaxis in chemotherapy patients was developed. PP was deﬁ ned as initiating 
prophylaxis with the ﬁ rst chemotherapy cycle. Model cycle length matches chemo-
therapy cycle length (CHOP-14:14 days, TAC: 21 days); model time horizon is the 
duration of chemotherapy (6 cycles). Cycle 1 FN risk with no prophylaxis was esti-
mated to be 21% for NHL CHOP-14 and 14% for BC TAC; all cycle relative risks 
of FN versus no prophylaxis for PP using Pegﬁ lgrastim, F6, and F11 were 0.25, 0.87 
and 0.61, respectively, based on published literature and meta-analyses. Pegﬁ lgrastim 
cost was estimated as c1686 per chemotherapy cycle; corresponding costs for F6 and 
F11 were c1347 and c2469 based on German national pricing. Incremental cost-
effectiveness ratios (ICERs) were calculated per FN events avoided. Costs and out-
comes were discounted (3%/year). Sensitivity analyses were performed. RESULTS: 
For NHL FN events per patient were 0.15, 0.76, and 0.47 for Pegﬁ lgrastim, F6, and 
F11, respectively. ICER for Pegﬁ lgrastim versus F6 was c1386 per FN avoided. For 
BC, corresponding FN events per patient were 0.09, 0.43, and 0.27. The ICER for 
Pegﬁ lgrastim versus F6 was c6651 per FN avoided. Pegﬁ lgrastim was dominant (less 
costly, more effective) compared with F11 in both populations. Results were most 
sensitive to baseline risk of FN, cost of prophylaxis and cost of FN events. CONCLU-
SIONS: Primary prophylaxis with pegﬁ lgrastim costs <c1400 per additional FN 
